MHC-HM405T-100μg / 询价
MHC-HM405T-500μg / 询价
MHC-HM405T-500μgx2 / 询价
- 客服电话
- 技术支持
Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Tetramer Protein
Recombinant Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Tetramer Protein is expressed from HEK293 with His tag and Avi tag at the C-Terminus,tetramer is assembled by biotinylated monomer and streptavidin. It contains Gly25-Thr305(HLA-A*02:01),Ile21-Met119(B2M) and SLLMWITQC peptide.[Accession | A0A140T913(HLA-A*02:01)&P61769(B2M)&SLLMWITQC]
The protein has a predicted MW of 258 kDa. Due to glycosylation, the protein migrates to 260-265 kDa under Non reducing (N) condition based on Tris-Bis PAGE result.
Less than 1EU per μg by the LAL method.
> 95% as determined by Tris-Bis PAGE
> 95% as determined by HPLC
Supplied as 0.22μm filtered solution in 20mM PB, 500mM NaCl (pH 7.4).
Valid for 12 months from date of receipt when stored at -80°C.
Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Tetramer on Tris-Bis PAGE under Non reducing (N) condition. The purity is greater than 95%.
The purity of Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Tetramer was greater than 95% as determined by SEC-HPLC.
Immobilized Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Tetramer, His Tag at 5μg/ml (100μl/Well) on the plate. Dose response curve for Anti-HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Antibody, hFc Tag with the EC50 of 2.3ng/ml determined by ELISA (QC Test).
Anti-HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Antibody, hFc Tag captured on CM5 Chip via Protein A can bind Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Tetramer, His Tag with an affinity constant of 0.09 nM as determined in SPR assay (Biacore T200).
NY-ESO-1 or New York esophageal squamous cell carcinoma 1 is a well-known cancer-testis antigen (CTAs) with re-expression in numerous cancer types. Its ability to elicit spontaneous humoral and cellular immune responses, together with its restricted expression pattern, have rendered it a good candidate target for cancer immunotherapy.
MHC; MY-ESO-1; CT6.1; LAGE-2; CTAG1; CTAG1B; ESO1CTAG; LAGE2A; NY-ESO-1
(1)Thomas R, Al-Khadairi G, Roelands J, Hendrickx W, Dermime S, Bedognetti D, Decock J. NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives. Front Immunol. 2018 May 1;9:947. doi: 10.3389/fimmu.2018.00947. PMID: 29770138; PMCID: PMC5941317.
